Bladder Cancer最新文献

{"title":"Organoid models in bladder cancer: From bench to bedside?","authors":"Hongda Zhao, Vincy Wing Sze Ho, Kang Liu, Xuan Chen, Hongwei Wu, Peter Ka-Fung Chiu, Lu-Yan Chan, Steffi Kar-Kei Yuen, David Ka-Wai Leung, Alex Qinyang Liu, Chris Ho-Ming Wong, Ivan Ching-Ho Ko, Chi Fai Ng, Dinglan Wu, Jeremy Yuen-Chun Teoh","doi":"10.1177/23523735251330404","DOIUrl":"https://doi.org/10.1177/23523735251330404","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC), one of the most prevalent and aggressive urological malignancies, poses significant challenges in diagnosis, treatment, and recurrence management. Patient-derived organoid provides new directions for the precision diagnosis and treatment of bladder cancer.</p><p><strong>Objective: </strong>To make a comprehensive summary of the current bladder cancer organoid studies.</p><p><strong>Methods: </strong>A comprehensive database search was conducted to provide an in-depth overview of the current state of bladder cancer organoid models, with a focus on their applications in basic research, clinical translation, and therapeutic discovery.</p><p><strong>Results: </strong>We summarized the current bladder cancer organoid studies, highlighting their advantages, such as genetic fidelity and high-throughput drug screening capabilities. Additionally, we also address the challenges, including their limited representation of the tumour microenvironment and technical complexity. Finally, we discuss future directions, including the integration of immunotherapy, the development of co-culture systems, and the exploration of non-invasive sampling methods and organoid-on-chip systems.</p><p><strong>Conclusions: </strong>Traditional pre-clinical models have inherent limitations in mimicking the complexity of human tumours. The emergence of organoid technology has offered a groundbreaking approach to address this challenge, providing an innovative tool for studying tumour biology, genetic alterations, drug screening, and personalized medicine in bladder cancer.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 2","pages":"23523735251330404"},"PeriodicalIF":1.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively.","authors":"Lauren N Kennedy, Caleb S Miller, Danica N May, Evan Fruhauf, Hadley W Wyre, Moben Mirza, Junqiang Dai, Jeffrey M Holzbeierlein, Hayley Stolzle, Moira Mulhern, Mihaela E Sardiu, Eugene K Lee","doi":"10.1177/23523735251319180","DOIUrl":"https://doi.org/10.1177/23523735251319180","url":null,"abstract":"<p><strong>Background: </strong>Radical cystectomy (RC) with urinary diversion (UD) is associated with substantial morbidity. Enhanced recovery after surgery protocols, increased robotic usage, and improvements in urinary diversion have been evaluated for their effects on health-related Quality of Life (HRQoL), however, results are mixed. How psychosocial traits inherent to the patient influence HRQoL outcomes is unknown in this population.</p><p><strong>Objective: </strong>This study aimed to evaluate resilience and its correlation with HRQoL in a cohort of patients undergoing RC for bladder cancer.</p><p><strong>Methods: </strong>Patients with bladder cancer undergoing RC with UD at the University of Kansas Medical Center were screened for prospective enrollment in this clinical trial (NCT06337305). The validated Connor-Davidson Resilience Scale 25 (CD-RISC), the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-BL-Cys), and the PROMIS 29-v2.0 were administered preoperatively, 2-3 weeks postoperatively, and at 90 days postoperatively. Patient demographics, pathology, and complication data were collected.</p><p><strong>Results: </strong>Between November 2020 and August 2022, 52 patients completed the survey data. Patients were stratified based on baseline resilience score. The higher resilience group scored 85.7, 85.0, and 81.9 compared to 64.9, 70.4, and 72.0 at the three time points which all remained statistically significant. Participant resilience scores using the CD-RISC did not correlate with quality-of-life measures using the PROMIS or FACT-Bl-Cys at baseline or two weeks but did correlate at 90 days (p < 0.01). Resilience did not correlate with the patient's pathology stage or 90-day complication data.</p><p><strong>Conclusions: </strong>Patients with higher baseline resilience maintain higher levels throughout the perioperative period and correlate with QOL.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 2","pages":"23523735251319180"},"PeriodicalIF":1.0,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trials corner issue 11(1).","authors":"Piyush K Agarwal, Cora N Sternberg","doi":"10.1177/23523735241309418","DOIUrl":"https://doi.org/10.1177/23523735241309418","url":null,"abstract":"","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735241309418"},"PeriodicalIF":1.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma.","authors":"Nobutaka Nishimura, Makito Miyake, Norimi Takamatsu, Kosuke Mieda, Kuniaki Inoue, Akira Tachibana, Keichi Sakamoto, Mikiko Onishi, Fumisato Maesaka, Takanosuke Yoshikawa, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.1177/23523735251317423","DOIUrl":"10.1177/23523735251317423","url":null,"abstract":"<p><strong>Background: </strong>In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemotherapy.</p><p><strong>Objective: </strong>We aimed to evaluate the potential advantages of platinum-based chemotherapy (Pl-CT) rechallenge after maintenance avelumab.</p><p><strong>Methods: </strong>A retrospective analysis involving 383 patients treated with first-line Pl-CT between 2015 and 2023 was conducted. Subsequent treatment strategies included Pl-CT or enfortumab vedotin (EV) following maintenance avelumab or pembrolizumab, and their benefit was evaluated.</p><p><strong>Results: </strong>Pl-CT rechallenge following maintenance avelumab did not show significant benefits, demonstrating lower response rates and shorter progression-free survival compared to EV. Conversely, both Pl-CT and EV following pembrolizumab showed similar efficacy.</p><p><strong>Conclusions: </strong>These findings suggest that in the current clinical landscape, EV might be a more preferable option than Pl-CT rechallenge subsequent to avelumab maintenance therapy, thereby influencing treatment decisions for metastatic urothelial carcinoma.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251317423"},"PeriodicalIF":1.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard vs extended lymphadenectomy for muscle invasive bladder cancer.","authors":"Edward M Messing","doi":"10.1177/23523735251314984","DOIUrl":"10.1177/23523735251314984","url":null,"abstract":"","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251314984"},"PeriodicalIF":1.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer.","authors":"Makito Miyake, Kota Iida, Nobutaka Nishimura, Sayuri Ohnishi, Takuya Owari, Tomomi Fujii, Yuki Oda, Tatsuki Miyamoto, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.1177/23523735251325100","DOIUrl":"10.1177/23523735251325100","url":null,"abstract":"<p><strong>Background: </strong>Metabolomic research and metabolomics-based biomarkers predicting treatment outcomes in bladder cancer remain limited.</p><p><strong>Objective: </strong>We explored the serum metabolites potentially associated with the risk of recurrence after intravesical Bacillus Calmette-Guérin (BCG) therapy.</p><p><strong>Methods: </strong>Two independent cohorts, a discovery cohort (n = 23) and a validation cohort (n = 40), were included in this study. Blood was collected before the induction of BCG therapy (pre-BCG blood; both discovery and validation cohorts) and after six doses of BCG (post-BCG blood; only discovery cohort). Metabolome analysis of serum samples was conducted using capillary electrophoresis time-of-flight mass spectrometry. The endpoint was intravesical recurrence-free survival, which was analysed using Kaplan-Meier estimates, the log-rank test, and the Cox proportional hazard model.</p><p><strong>Results: </strong>Of the 353 metabolites quantified, nine (2.5%) and four (1.1%) were significantly upregulated and downregulated, respectively. The heatmap of hierarchical clustering analysis and principal coordinate analysis for the fold changes and in serum metabolites differentiated 10 recurrent cases and 13 non-recurrent cases in the discovery cohort. A metabolome response-based scoring model using 16 metabolites, including threonine and N6,N6,N6-trimethyl-lysine effectively stratified the risk of post-BCG recurrence. Additionally, pre-BCG metabolome-based score models using six metabolites, octanoylcarnitine, S-methylcysteine-S-oxide, theobromine, carnitine, indole-3-acetic acid, and valeric acid, were developed from the discovery cohort. Univariate and multivariate analyses confirmed a high predictive accuracy in the validation and combination cohorts.</p><p><strong>Conclusions: </strong>We demonstrated that numerous types of serum metabolites were altered in response to intravesical BCG and developed high-performance score models which might effectively differentiated the risk of post-BCG tumour recurrence.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251325100"},"PeriodicalIF":1.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup />.","authors":"Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black","doi":"10.1177/23523735251319185","DOIUrl":"10.1177/23523735251319185","url":null,"abstract":"<p><p>The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251319185"},"PeriodicalIF":1.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of bladder cancer in kidney transplant recipients: A narrative review.","authors":"Khi Yung Fong, Ee Jean Lim, Wei Zheng So, Edwin Jonathan Aslim, Ho Yee Tiong, Valerie Huei Li Gan","doi":"10.1177/23523735251321986","DOIUrl":"10.1177/23523735251321986","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer in the setting of previous a kidney transplant (KT) is challenging to manage due to complex medical and surgical considerations.</p><p><strong>Objective: </strong>To provide a comprehensive evaluation of the scope of management of bladder cancer in KT patients, and describe the controversies surrounding these management options.</p><p><strong>Methods: </strong>A systematic review of studies reporting management of KT patients with bladder cancer and involving ≥3 patients was performed. A narrative review was also performed for various aspects of management such as pathophysiology, surgical considerations, intravesical therapy, immunosuppression and oncological surveillance.</p><p><strong>Results: </strong>Bladder cancer incidence in KT recipients is 2.8-4.1 times higher than the general population, and there is a notable association with aristolochic acid nephropathy as well as BK virus oncogenesis. Regarding surgical treatment, transurethral resection is preferred for non-muscle invasive tumors, and intravesical BCG for intermediate- and high-risk patients appears to be underutilized despite its safety and associated reduction in recurrence. Radical cystectomy with limited pelvic lymph node dissection, urinary diversion, and consideration of bilateral nephroureterectomy appears to be the safest method of oncological control in muscle-invasive tumors. A switch in immunosuppressive regimens to mTOR inhibitors may be considered in lieu of its antitumor effects. Routine surveillance in KT patients with risk factors for bladder cancer is challenging and may be warranted especially in the Asian population which has a higher rate of urothelial malignancy.</p><p><strong>Conclusions: </strong>This review provides a thorough summary of management strategies for bladder cancer in the setting of previous KT.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251321986"},"PeriodicalIF":1.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives.","authors":"Kentaro Yoshihara, Kagenori Ito, Takahiro Kimura, Yusuke Yamamoto, Fumihiko Urabe","doi":"10.1177/23523735251322017","DOIUrl":"10.1177/23523735251322017","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is one of the most prevalent malignancies, and the mechanisms underlying its progression and the role of the tumor microenvironment (TME) are unclear. Recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) enable detailed analysis of the cellular heterogeneity, gene expression, and cell-cell interactions in bladder diseases.</p><p><strong>Methodology: </strong>We conducted a comprehensive search for recent articles that have investigated bladder diseases using scRNA-seq and ST.</p><p><strong>Results: </strong>scRNA-seq and ST have led to significant discoveries in bladder disease research. These technologies have enabled the identification of multiple molecular subtypes within individual tumors and of the mechanisms of treatment resistance. Additionally, molecular differences based on gender have been explored, explaining the heterogeneity of the incidence and progression of bladder cancer. These findings deepen our understanding of the pathology of bladder diseases and highlight the transformative potential of scRNA-seq and ST in identifying novel biomarkers and therapeutic targets.</p><p><strong>Conclusions: </strong>Integrating scRNA-seq and ST has considerably enhanced our understanding of tumor heterogeneity and the tumor microenvironment within tissues. These insights may lead to the development of personalized therapies and the improvement of patient outcomes. Several challenges, such as technical limitations and access difficulties, need to be addressed for the future clinical application of these technologies.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251322017"},"PeriodicalIF":1.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer.","authors":"Surish P Shanmugam, Yuzhen Zhou, Isabella Stelter, Timothy Hanlon, Raie T Bekele, Joaquim Bellmunt, Zoltan Szallasi, Kent W Mouw","doi":"10.1177/23523735251317865","DOIUrl":"10.1177/23523735251317865","url":null,"abstract":"<p><strong>Background: </strong>Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in either the homologous recombination (HR) or nucleotide excision repair (NER) pathway that has the potential to impact sensitivity to specific classes of therapeutics.</p><p><strong>Objective: </strong>Define the impact of HR or NER deficiency on sensitivity to ADC payloads alone or in combination with DNA repair targeted agents in bladder cancer.</p><p><strong>Methods: </strong>Isogenic cell pairs with versus without HR or NER deficiency were profiled using DNA repair and drug sensitivity assays. Sensitivity to the ADC payloads monomethyl auristatin E (MMAE) and SN-38 alone or in combination with small molecule inhibitors of poly(ADP-ribose) polymerase (PARP), ATR, or USP1 were measured using cell viability assays.</p><p><strong>Results: </strong>BRCA2 loss was sufficient to confer an HR deficient phenotype and increase sensitivity to cisplatin and PARP inhibition in bladder cancer cell lines. HR deficiency, but not NER deficiency, increased sensitivity to MMAE and SN-38 in bladder cancer cells. The combination of SN-38 and PARP inhibition displayed synergistic cell killing independent of HR or NER status.</p><p><strong>Conclusion: </strong>HR and NER deficiency have distinct impacts on sensitivity to cisplatin and ADC payloads in bladder cancer preclinical models.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251317865"},"PeriodicalIF":1.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}